A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01878617

Recruitment Status : Active, not recruiting

First Posted : June 17, 2013

Last Update Posted : December 6, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Genentech, Inc.

National Cancer Institute (NCI)

Information provided by (Responsible Party):

St. Jude Children's Research Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	January 2025
Estimated Study Completion Date :	January 2028

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Khan RB, Patay Z, Klimo P, Huang J, Kumar R, Boop FA, Raches D, Conklin HM, Sharma R, Simmons A, Sadighi ZS, Onar-Thomas A, Gajjar A, Robinson GW. Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. Neuro Oncol. 2021 Sep 1;23(9):1586-1596. doi: 10.1093/neuonc/noab030.

To Top